Pharma

Health-tech startup Tata 1mg eyes 500 offline stores by year-end

The move signals a sharper push towards omnichannel growth amid continued regulatory uncertainty in e-pharmacy

Supriya Life Sciences bets on regulated markets with new facility

The Mumbai-based pharma company has commissioned a ₹165-crore formulations plant at Ambernath to support contract manufacturing and strengthen its presence in regulated global markets

India-New Zealand trade deal finalised: Which sectors are set to gain?

The deal includes sweeping tariff cuts, expanded services access, enhanced labour mobility and a long-term investment commitment

Biocon launches drugs for diabetes and obesity treatment in Netherlands

The Netherlands launch builds on Biocon's entry into the UK in February, where it received regulatory approval for liraglutide from the Medicines and Healthcare Products Regulatory Agency

300 products hold huge potential for Indian exporters in Russia: Official

As many as 300 products, including that of engineering goods, pharma, agri, and chemicals, hold huge potential for Indian exporters to push their shipments to Russia as the two countries target USD 100 billion trade by 2030, an official said. At present, India's exports of these goods to Russia stood at USD 1.7 billion, as against Russia's USD 37.4 billion in imports. "This stark disparity demonstrates the substantial complementary export space India can target," the official said, adding increasing exports will also help India bridge its trade deficit with Russia, which stood at USD 59 billion. These high-potential products have been selected by the commerce ministry by analysing complementary basket of products -- mapping India's supply visa-a-vis Russia's demand across key sectors, the official added. The most promising areas mirror India's rising global strengths are engineering goods, pharmaceuticals, chemicals and agriculture, all of which correspond to substantial unmet dema

Novo Nordisk moves HC to stop Sun Pharma's weight-loss drug launch

The dispute centres on Novo Nordisk's Indian patents for semaglutide, which it markets globally as Ozempic and Wegovy for Type 2 diabetes and weight management

Generic drugmakers to slash price plans as Novo cuts Wegovy rates

Novo Nordisk cut Wegovy prices by up to 37 per cent across different doses to compete with rival drug Mounjaro from Eli Lilly

Rupee's fall to boost IT & Pharma, but is it too soon to bet? Analysts weigh in

India’s rupee has fallen to a new low against the US dollar, raising concerns across markets. But analysts say not everyone loses.

Novo Nordisk cuts weight-loss drug Wegovy prices by up to 37% in India

Move comes in a bid to gain more space in India's anti-obesity market dominated by Mounjaro

Eli Lilly to buy gene therapy developer Adverum in about $262 mn deal

The deal will give Lilly access to Adverum's gene therapy candidate, Ixo-vec, and underscores the U.S. drugmaker's focus on such treatments

Govt to bring law for strict quality checks, monitoring of drugs, cosmetics

Amid growing demand for stricter compliance with safety and quality control norms for medical products, the Centre is framing a law to strengthen the legal framework for drug quality testing and market surveillance, along with regulation of medical devices and cosmetics. One of the major reasons behind the drafting of the law is the repeated complaints and concerns flagged by health regulators across the globe, including the WHO, over serious quality lapses by Indian drug manufacturers. The draft of the 'Drugs, Medical Devices and Cosmetics Act 2025', which the government aims to introduce in the upcoming Winter session of Parliament, was presented by Drugs Controller General of India (DCGI) Dr Rajeev Raghuvanshi at a high-level meeting of the Union health ministry held on Tuesday, the sources said. The meeting was chaired by Union Health Minister J P Nadda. During the meeting, senior officials from the Drugs Controller General of India (DCGI) and the Central Drugs Standard Control

Tamil Nadu cancels licence of cough syrup maker linked to child deaths

"The manufacturing licenses of Sresan Pharmaceuticals have been completely cancelled, and the company has been shut down," the state government said in a statement

Mohan Yadav blames Tamil Nadu for poor cooperation in cough syrup case

After 24 child deaths linked to toxic cough syrup, Madhya Pradesh CM Mohan Yadav accuses Tamil Nadu of not cooperating in the investigation into drug safety lapses

DCGI urges state drug controllers to test pharma batches before release

The Drugs Controller General of India (DCGI) has urged all drug controllers of the states and Union Territories to ensure testing of raw materials and finished formulations of pharmaceutical products before releasing them in the market in the wake of children's deaths allegedly due to the consumption of contaminated cough syrup in Madhya Pradesh and Rajasthan. Five children from Madhya Pradesh are in a critical condition, while 20 have died due to kidney infections caused by the consumption of the "contaminated" cough syrup, containing Diethylene Glycol (DEG) and Ethylene Glycol (EG). Besides, at least three children have allegedly died in Rajasthan after consuming cough syrup in different districts of the state. In an advisory, the DCGI said that during recent inspections at manufacturing facilities and in the investigations of the drugs declared as 'Not of Standard Quality', it was found that several manufacturers are not testing each batch of excipients and active ingredients for

A deadly dose of neglect: Bitter truth behind cough syrup scare

Bottled negligence: DEG contamination exposes gaps in inspections, leaving pharma units from Gujarat to Kerala under the microscope

Lupin to invest $250 mn in new US facility for critical respiratory drugs

Drug firm Lupin on Wednesday said it will set up a new manufacturing facility in Coral Springs, Florida, entailing an investment of USD 250 million. With a projected cumulative investment of USD 250 million, including research & development, infrastructure and capital expenditures over a five-year period, the new site will have the capacity to accommodate the production of more than 25 critical respiratory medicines, the Mumbai-based drug maker said in a regulatory filing. The Florida-based plant would produce products like albuterol inhalers for children with asthma, it added. By strengthening domestic manufacturing and enhancing supply chain diversification, this critical project will enhance medicine security and strengthen the company's position as a global respiratory leader, it said. Locally, the infrastructure will generate over 200 new long-term, skilled jobs by 2030 in Broward County. "The expansion of Lupin's footprint in Coral Springs is a core part of our growth ...

Kerala stops sale of Sresan drugs after Tamil Nadu cancels company licence

The Kerala government on Tuesday banned the distribution of medicines manufactured by Tamil Nadu-based Sresan Pharmaceuticals. The decision follows steps by the Tamil Nadu Drugs Controller to cancel the company's licence, state Health Minister Veena George said. Sales of Respifresh TR, manufactured by a Gujarat-based firm, were also stopped immediately after the drug was found to be substandard, the minister said in a statement. There are five distributors in the state supplying this medicine, and they have been instructed to stop distribution, George said. Strict action will be taken against those selling this medicine. Those in possession of this drug are requested not to use it. These medicines are not distributed through government hospitals. She added that strict action would be initiated against establishments that provide medicines to children under the age of 12 without a prescription from an authorised doctor. The ban comes after reports that 14 children in Chhindwara, M

Punjab bans Coldrif, even as PIL in SC seeks probe on cough syrup deaths

With this, the state joins Maharashtra, Kerala and Tamil Nadu, who have already announced bans on the cough syrup

Eli Lilly's Mounjaro logs ₹80 crore in September, India's No. 2 drug

Eli Lilly's weight-loss injection Mounjaro saw a 42% jump in September sales, touching Rs 80 crore as more patients shift to higher doses amid rising demand

Rubicon Research sets IPO price band at ₹461-475; check key dates, lot size

Rubicon Research IPO will open for subscription on Thursday, October 9, 2025, and close on Monday, October 13, 2025